MindBio Therapeutics Corp. (CSE:MBIO)

Canada flag Canada · Delayed Price · Currency is CAD
0.9000
-0.1200 (-11.76%)
At close: Mar 20, 2026
Market Cap4.31M +27.8%
Revenue (ttm)n/a
Net Income-5.49M
EPS-0.01
Shares Out4.79M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,465
Average Volume8,303
Open0.9800
Previous Close1.0200
Day's Range0.9000 - 0.9800
52-Week Range0.5000 - 6.0000
Beta-1.02
RSI47.46
Earnings DateMay 13, 2026

About MindBio Therapeutics

MindBio Therapeutics Corp., together with its subsidiaries, engages in researching, developing, and testing psychedelic substances as a potential treatment for the management of various mental health conditions in Australasia. Its lead drug candidate is MB22001, a form of lysergic acid diethylamide in Phase 2A trials. The company also develops wearable devices to collect biometric data in mental health patients taking psychedelic medicines; and invests in research that forms the basis for developing novel and clinically proven treatments for de... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2021
Country Canada
Stock Exchange Canadian Securities Exchange
Ticker Symbol MBIO
Full Company Profile

Financial Performance

Financial numbers in AUD Financial Statements